PF-06835375

BIOLOGICAL2 trials

Sponsors

Pfizer

Conditions

Primary Immune ThrombocytopeniaRheumatoid ArthritisSystemic Lupus Erythematosus

Phase 1

Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

CompletedNCT03334851

PfizerRheumatoid Arthritis, Systemic Lupus Erythematosus

Start: 2017-11-17End: 2022-02-15Updated: 2023-10-30

Phase 2

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

RecruitingNCT05070845

PfizerPrimary Immune Thrombocytopenia

Start: 2022-02-02End: 2028-08-02Target: 91Updated: 2026-05-12

Related Papers

A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.

2024-06-068 citations